Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proline SCHEMBL1740644 | 0.77 | TP53 (0.42) | MEN1KMT2APRCPDPP7 | |
| Proline SCHEMBL1740645 | 0.77 | TP53 (0.42) | MEN1KMT2APRCPDPP7 | |
| SCHEMBL42677 | 0.77 | TP53 (0.38) | ACE | |
| SCHEMBL42674 | 0.77 | TP53 (0.38) | ACE | |
| Proline SCHEMBL5409741 | 0.77 | MEN1 (0.38) | ACEMEN1ALDH1A1CYP1A2THRB | |
| Proline SCHEMBL26181011 | 0.76 | MEN1 (0.42) | MEN1KMT2APRCPDPP7 | |
| Proline SCHEMBL29191180 | 0.76 | MEN1 (0.46) | MEN1ALDH1A1CYP1A2THRBALOX15 | |
| Proline SCHEMBL29191182 | 0.76 | MEN1 (0.46) | MEN1ALDH1A1CYP1A2THRBALOX15 | |
| SCHEMBL8526747 | 0.76 | DPP7 (0.47) | MEN1ALDH1A1CYP1A2CYP2C19KMT2A | |
| SCHEMBL34461082 | 0.76 | DPP7 (0.47) | MEN1ALDH1A1CYP1A2CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120244594-A9 | Immunoaffinity isolation of modified peptides from complex mixtures | CELL SIGNALING TECHNOLOGY, INC. | 2012-09-27 | — | — | US | claimed |
| US-20110053242-A1 | Immunoaffinity isolation of modified peptides from complex mixtures | CELL SIGNALING TECHNOLOGY, INC. | 2011-03-03 | — | — | US | claimed |
| US-7300753-B2 | Immunoaffinity isolation of modified peptides from complex mixtures | CELL SIGNALING TECHNOLOGY, INC. | 2007-11-27 | — | — | US | claimed |
| EP-1012178-B1 | INHIBITORS OF PHOSPHOSERINE AND PHOSPHOTHREONINE-PROLINE-SPECIFIC ISOMERASES | BETH ISRAEL HOSPITAL (US) | 2006-07-12 | — | — | EP | claimed |
| US-20050003450-A1 | Immunoaffinity isolation of modified peptides from complex mixtures | CELL SIGNALING TECHNOLOGY, INC. | 2005-01-06 | — | — | US | claimed |
| US-20030109423-A1 | Inhibitors of phosphoserine and phosphothreonine-proline-specific isomerases | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER AND BETH ISRAEL DEACONESS MEDICAL CENTER | 2003-06-12 | — | — | US | claimed |
| US-6462173-B1 | PEPTIDE MIMETIC ANTIPROLIFERATIVE, ANTITUMOR, ANTICARCINOGENIC, ANTIAPOPTOTIC AND ANTIMITOTIC AGENTS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER (DE) | 2002-10-08 | — | — | US | claimed |
| EP-1012178-A1 | INHIBITORS OF PHOSPHOSERINE AND PHOSPHOTHREONINE-PROLINE-SPECIFIC ISOMERASES | Beth Israel Deaconess Medical Center (US) | 2000-06-28 | — | — | EP | claimed |
| WO-1999012962-A1 | INHIBITORS OF PHOSPHOSERINE AND PHOSPHOTHREONINE-PROLINE-SPECIFIC ISOMERASES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 1999-03-18 | — | — | WO | claimed |
| US-10407712-B2 | Methods, compositions and kits for high throughput kinase activity screening using mass spectrometry and stable isotopes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180119198-A1 | Methods, Compositions and Kits for High Throughput Kinase Activity Screening Using Mass Spectrometry and Stable Isotopes | HARVARD COLLEGE (US) | 2018-05-03 | — | — | US | disclosed |
| EP-2347263-B1 | METHODS, COMPOSITIONS AND KITS FOR HIGH THROUGHPUT KINASE ACTIVITY SCREENING USING MASS SPECTROMETRY AND STABLE ISOTOPES | HARVARD COLLEGE (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9587013-B2 | Immunoaffinity isolation of modified peptides from complex mixtures | CELL SIGNALING TECHNOLOGY, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150037891-A1 | METHODS FOR ENHANCING INFECTIVITY OF RETROVIRUSES | SAPHIRE ANDREW (US) | 2015-02-05 | — | — | US | disclosed |
| WO-2000048621-A2 | METHODS AND COMPOSITIONS FOR REGULATING PROTEIN-PROTEIN INTERACTIONS | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2000-08-24 | — | — | WO | disclosed |
| EP-1012178-A1 | INHIBITORS OF PHOSPHOSERINE AND PHOSPHOTHREONINE-PROLINE-SPECIFIC ISOMERASES | Beth Israel Deaconess Medical Center (US) | 2000-06-28 | — | — | EP | disclosed |
| EP-1012178-A1 | INHIBITORS OF PHOSPHOSERINE AND PHOSPHOTHREONINE-PROLINE-SPECIFIC ISOMERASES | Beth Israel Deaconess Medical Center (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999012962-A8 | INHIBITORS OF PHOSPHOSERINE AND PHOSPHOTHREONINE-PROLINE-SPECIFIC ISOMERASES | BETH ISRAEL HOSPITAL (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999012962-A1 | INHIBITORS OF PHOSPHOSERINE AND PHOSPHOTHREONINE-PROLINE-SPECIFIC ISOMERASES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 1999-03-18 | — | — | WO | disclosed |
| WO-1999012962-A1 | INHIBITORS OF PHOSPHOSERINE AND PHOSPHOTHREONINE-PROLINE-SPECIFIC ISOMERASES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 1999-03-18 | — | — | WO | disclosed |